Epirubicin in non-oat cell lung cancer--response rates and the importance of immunopathology: a Northern California Oncology Group Study.
D000328:Adult; D000368:Aged; D004317:Doxorubicin / Q000009:adverse effects / Q000627:therapeutic use*; D015251:Epirubicin; D005260:Female; D006331:Heart Diseases / Q000139:chemically induced; D006801:Humans; D007124:Immunoenzyme Techniques; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D013194:Staining and Labeling; D013223:Statistics as Topic; D013237:Stereoisomerism
D015251:Epirubicin; D004317:Doxorubicin